Federal contract award
75A50122C00008
HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $38.0M |
| Current contract value | $38.0M |
| Potential contract value / ceiling | $38.0M |
| Start date | Nov 29, 2021 |
| Current end date | Sep 30, 2029 |
| Potential end date | Sep 30, 2029 |
| Latest award activity | Mar 4, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 12 of 12 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Mar 4, 2026 | P00011 | $0 | HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES. |
| Sep 24, 2025 | P00010 | $0 | HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES. |
| Sep 15, 2025 | P00009 | $-15.6M | EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING::EOI BILATERAL MODIFICATION TO DESCOPE WORK AND DEOBLIGATE FUNDS. |
| Jun 17, 2025 | P00008 | $0 | COR WILL BE CHANGED TO LAKSHMI JAYASHANKAR AND CO WILL BE CHANGED TO JILL JOHNSON. |
| Sep 15, 2023 | P00007 | $0 | HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES. |
| Jun 8, 2023 | P00006 | $-342 | HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES. |
| Jan 27, 2023 | P00005 | $-270 | HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES. |
| Jan 11, 2023 | P00004 | $0 | HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES. |
| Jun 29, 2022 | P00003 | $0 | HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES. |
| Jun 8, 2022 | P00002 | $33.3M | HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES. |
| May 26, 2022 | P00001 | $0 | HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES. |
| Nov 29, 2021 | 0 | $20.4M | HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES. |
Estimated positioning window
Sep 30, 2028 – Mar 30, 2029
50/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 50/100. Available recorded signals: 45 points.
- Contract end 2029-09-30 (1071 days from calculation)
- +15 points
- 121 historical awards in this buyer and category group
- +15 points
- 12 recorded award transactions
- +10 points
- Latest award action: 2026-03-04
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.